A Phase 1b Trial Of Specific Immunotherapy For Recurrent Respiratory Papillomatosis
Funder
National Health and Medical Research Council
Funding Amount
$141,208.00
Summary
This project will determine whether immunisation can be used to effectively treat an existing infection. To date, immunisation has only been used to prevent infection, but there are many chronic infections where intervention might help the body's defences to to a better job and clear the chronic infection. In this study, we will work out whether this approach can be applied to a virus infection ( papillomavirus) which is associated with cancer. We will test immunisation against a chronic and lif ....This project will determine whether immunisation can be used to effectively treat an existing infection. To date, immunisation has only been used to prevent infection, but there are many chronic infections where intervention might help the body's defences to to a better job and clear the chronic infection. In this study, we will work out whether this approach can be applied to a virus infection ( papillomavirus) which is associated with cancer. We will test immunisation against a chronic and lifethreatening disorder in which warts grow in the respirarory tract, as there is currently no satisfactory treatment for this. If the project is successful we may also learn which blood tests are likely to predict the outcome of immunisation to treat infection.Read moreRead less
The Population Impact Of Human Papillomavirus Vaccination On Circulating Genotypes
Funder
National Health and Medical Research Council
Funding Amount
$249,259.00
Summary
Infection with human papillomavirus (HPV) is very common. Persistent infection can cause abnormal changes to cervical cells as found on Pap smears and if untreated, over time can develop into cervical cancer. Recently, a vaccine was introduced in Australia for women aged 12-26. To monitor the effectiveness of this vaccine, young women aged 18-22 will be asked to self-collect a sample for HPV detection which will determine if HPV types targeted by vaccine are reducing in prevalence.